Gpn3 is required for RNA polymerase II (RNAPII) nuclear targeting. Here, we investigated the effect of a cancer-associated Q279* nonsense mutation in Gpn3 cellular function. Employing RNAi, we replaced endogenous Gpn3 by wt or Q279* RNAi-resistant Gpn3R in epithelial model cells. RNAPII nuclear accumulation and transcriptional activity were markedly decreased in cells expressing only Gpn3R Q279*. Wild-type Gpn3R localized to the cytoplasm but a fraction of Gpn3R Q279* entered the cell nucleus and inhibited Gpn1-EYFP nuclear export. This property and the transcriptional deficit in Gpn3R Q279*-expressing cells required a PDZ-binding motif generated by the Q279* mutation. We conclude that an acquired PDZ-binding motif in Gpn3 Q279* caused Gpn3 nuclear entry, and inhibited Gpn1 nuclear export and Gpn3-mediated RNAPII nuclear targeting.
The Gpn protein family comprises Gpn1, Gpn2, and Gpn3. These proteins share some degree of sequence identity, as all three derived from a single Gpn common ancestor present in archaea. Members of this family are characterized for having an invariable glycine-proline-asparagine motif, and the short sequences that define guanine nucleotide-binding proteins [1] . All three members are universally conserved in eukaryotic cells and are essential proteins in yeast [2] . Gpn3 was originally identified as a protein that specifically interacts with the oligomerization domain of Apaf-1 and named Parcs (from pro-apoptotic protein required for cell survival) [3] . Gpn3 also interacts with RNA polymerase II (RNAPII), and is required for the nuclear localization of this enzyme in both, human [4, 5] and yeast [6] cells. This conserved function may be at least part of the reason for Gpn3 being an essential protein, as RNAPII synthesizes all mRNAs in eukaryotic cells [7, 8] . Gpn3 forms a tight complex with Gpn1, and being part of this protein complex is essential for the stability of both proteins [9] .
In order to understand the origin of cancer and design rational therapeutics, the genomic alterations present in the most common type of tumors are being investigated. The cancer cell genome sequence and genetic changes found are organized at several databases, such as the Catalogue of Somatic Mutations in Cancer (COSMIC). Some of these mutations are 'driver' mutations, as they are at the core of generating the transformed phenotype characteristic of Abbreviations COSMIC, Catalogue of Somatic Mutations in Cancer; DMEM, Dulbecco's modified Eagle's medium; EU, 5-Ethynyluridine; HRP, horseradish peroxidase; RNAPII, RNA polymerase II.
cancer cells. However, many mutations belong to the 'passenger' class, i.e., mutations that accumulate secondarily to the transformed phenotype due to faults in the DNA repair machinery or other causes, but they do not critically contribute to the cancer cell properties. Our interest to investigate the cellular function of Gpn3 under physiological and pathological conditions led us to notice in COSMIC a series of mutations in the GPN3 gene. GPN3 mutations occur in several cancer types but their impact on Gpn3 function, or the contribution of these Gpn3 mutants to the transformed phenotype in cancer cells is unknown.
In this study, we investigated the functional relevance of a C to T mutation at the Gpn3 cDNA position 835, a mutation that has been described in two different cancer patients, one with colon cancer [10] and one with an aggressive skin carcinoma [11] . This mutation changes codon 279 in Gpn3 from glutamine to a nonsense stop codon, which eliminates the last six amino acids in Gpn3, but whose functional relevance is unknown. We found that the Q279* mutation has a significant impact on Gpn3 function at the cellular level. Our results demonstrated that in our epithelial MCF-12A model cells Gpn3 Q279* was defective in performing the best-known function of Gpn3, i.e., to mediate the nuclear accumulation of Rpb1, the largest RNAPII subunit. Importantly, the cytoplasmic retention of Rpb1 was relevant for RNAPII function, as global transcriptional activity in cells expressing exclusively the Gpn3 Q279* nonsense mutant was markedly decreased compared to control cells expressing wild-type Gpn3. Gpn3 Q279* also displayed an anomalous gain of function and, in contrast to Gpn3 wild-type, was able to recruit Gpn1-EYFP from the cytoplasm to the cell nucleus in transiently transfected HEK293T cells. Disrupting the PDZ domain-binding motif class 3 formed at the new C-terminal end in Gpn3 Q279*, identified at the ELM (The Eukaryotic Linear Motif) database [12] , by adding or removing one single amino acid to Gpn3 Q279*, eliminated its ability to recruit Gpn1-EYFP to the cell nucleus, but most importantly, rescued Gpn3 Q279* defect to support RNAPII transcription. We concluded that the Gpn3 Q279* cancer mutant displayed important functional alterations at the cellular level, very likely explained by a gain of function given by a PDZ domain-binding motif generated at the new C-terminus of Gpn3 Q279*. It will of great interest to evaluate in the near future the contribution of Gpn3 Q279*, if any, to the generation, progression or maintenance of the transformed phenotype in colon and skin cancer cells.
Materials and methods

Antibodies and reagents
Mouse monoclonal anti-tubulin antibody, anti-mouse and anti-rabbit immunoglobulin G conjugated to horseradish peroxidase (HRP) were obtained from Sigma (St. Louis, MO, USA). The rabbit polyclonal anti-Gpn3 antibody was generated employing a full-length, histidine-tagged Gpn3 recombinant protein as antigen. Mouse anti-Rpb1 antibody (8WG16) was purchased from Covance (Emerville, CA, USA). Chemicals and reagents were obtained from Sigma and all tissue culture reagents from Invitrogen (Carlsbad, CA, USA). Full-length cDNA for human Gpn3 was subcloned into the BglII and HindIII sites of the pEYFP vector with a stop codon inserted before the coding region for EYFP. A NotI site was included in the primer before the HindIII site to allow the release and subcloning of cDNA Gpn3 with HindIII and NotI in the pLNCX2 retroviral vector. The RNAi-resistant form of Gpn3 wt (Gpn3R) contained three silent mutations in the cDNA sequence region complementary to the shRNA g193 but Gpn3 amino acid sequence was unchanged [9] . Gpn3R mutants (Q279*, E280*, F278*, E276A/Q279*) were generated by site-directed PCR mutagenesis using Gpn3R wt in pEYFP as template. shRNA-mediated depletion of endogenous Gpn3
Cell culture conditions
To stably suppress the expression of endogenous Gpn3 we employed a retroviral vector expressing the shRNA g193.
As a control we used the shRNA g239. Retroviruses were produced as above in HEK293T/17 cells and used to infect the human MCF-12A cells as previously described [4] .
Transient expression of Gpn1-EYFP and wt and mutant versions of Gpn3 in HEK293T/17 cells
HEK293T/17 cells were transfected with purified DNA (1 lg each) by the calcium phosphate method, and after 48 h cells were washed twice in PBS and fixed with 3.7% formaldehyde in PBS for 15 min at room temperature. After rinsing with PBS, cells were permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. Cells were counterstained with DAPI to visualize nuclei.
Assessment of RNA synthesis at the single cell level
To assess RNA synthesis, we employed the method of 5-ethynyluridine labeling [13] . Briefly, MCF-12A cells were grown in tissue culture plastic dishes in complete cell culture medium. One millimolar 5-Ethynyluridine (EU; Invitrogen) was added for 1 h at 37°C. After EU labeling, cells were washed with phosphate buffered saline solution (PBS) and fixed with 3.7% formaldehyde in PBS for 15 min. Fixed cells were rinsed twice with PBS and stained with a fluorescent azide that reacted with incorporated EU into RNA (Invitrogen).
Western blot analysis
Cells were washed with ice-cold PBS and scraped into lysis buffer containing 50 mM Tris (pH 7.4), 1% Triton X-100, 150 mM NaCl, 1 mM MgCl 2 , 1 mM EDTA, 1 mM DTT and 1 mM PMSF. After incubating cells for 20 min on ice, the lysates were cleared by centrifugation. Samples were separated on SDS/PAGE gels and electrophoretically transferred in a semidry system to poly(vinylidene difluoride) membranes. Western blot assays were performed as previously described [4] .
Immunofluorescence MCF-12A or HEK293T/17 cells were washed twice with PBS and fixed with 3.7% formaldehyde in PBS (pH 7.4) for 15 min at room temperature. Cells were rinsed with PBS and permeabilized and blocked in one step by incubating them in PBS containing 0.2% Triton-X100 and 10% fetal bovine serum for 15 min at room temperature. Cells were incubated overnight with mouse anti-Rpb1 antibody at a 1 : 500 dilution. After removing the primary antibody, cells were washed three times for three min each in PBS, followed by a 30-min incubation with Alexa Fluor 568-conjugated anti-mouse secondary antibody acquired from Molecular Probes (Thermo Fisher Scientific, Waltham, MA, USA). Finally, cells were counterstained with DAPI to visualize nuclei. Images were collected with an Olympus inverted microscope equipped with an evolution MP camera.
Results
The colon and skin cancer Gpn3 Q279* nonsense mutant is defective to support RNAPII nuclear targeting
The main goal of this study was to investigate, at a cellular level, the functional integrity of the Gpn3 Q279* nonsense mutant identified during the exome sequencing of colon [10] and skin [11] cancer patients. The formation of a stop codon instead of the original glutamine codon at position 279 eliminates only the most C-terminal six amino acids in Gpn3. With the help of retroviruses, we generated MCF-12A human mammary epithelial cells stably expressing untagged forms of RNAi-resistant Gpn3 (Gpn3R), either wild-type Gpn3R or Gpn3R Q279*. Both Gpn3R versions contain silent mutations that did not change the amino acid sequence but made the Gpn3 mRNA resistant (Gpn3R) to the shRNA g193 used later to suppress the expression of endogenous Gpn3. Gpn3R wt or Gpn3R Q279* expressing cells generated as described in Materials and methods were subsequently infected with a second retrovirus expressing the shRNA g193, which is highly effective to suppress Gpn3 expression [4] , or the shRNA g239, an ineffective shRNA used as a control. The Gpn3R Q279* mutant protein showed a slightly faster electrophoretic mobility than Gpn3R wild-type but this was not always evident, as there is a difference of only six aminoacids (Fig. 1A) . However, cells infected with the shRNA g239 had higher levels of total Gpn3 protein, the sum of endogenous and RNAi-resistant Gpn3R expressed from the retrovirus, than the extracts prepared from the corresponding cells expressing the shRNA g193, containing the RNAi-resistant Gpn3R but not the endogenous protein (Fig. 1A) . As the bestknown function for Gpn3 is to participate in the nuclear accumulation of RNAPII, we next evaluated the ability of Gpn3 Q279* to mediate this process. Rpb1, the largest subunit of RNAPII, was exclusively nuclear in Gpn3R wt-expressing cells infected with the retrovirus encoding the shRNAs g193 or g239, and in Gpn3R Q279*-expressing cells infected with a retrovirus with the shRNA control g239 (Fig. 1A,B) . In contrast, Rpb1 was substantially retained in the cytoplasm of cells expressing the Gpn3R Q279* mutant and infected with a retrovirus expressing the shRNA g193 (Fig. 1B,C) , indicating that, in contrast to Gpn3R wt, the Gpn3R Q279* mutant was unable to support RNAPII nuclear targeting. To express the results in a quantitative manner, we assessed the Rpb1 nucleus/cytoplasm fluorescence ratio using the program IMAGE J (NIH, Bethesda, MD, USA). These results showed that the nucleus/cytoplasm Rpb1 fluorescence ratio is around fourfold higher in cells expressing Gpn3R wt and the shRNAs g239 or g193, and in Gpn3R Q279* cells expressing the shRNA g239, than in Gpn3R Q279* cells expressing the shRNA g193 (Fig. 1C) . We conclude that, in contrast to wt Gpn3, the Gpn3 Q279* cancer mutant was functionally defective to target Rpb1, and very likely the whole RNAPII, to the cell nucleus.
Global transcriptional activity is markedly reduced in cells expressing only the Gpn3 Q279* nonsense cancer mutant
We next asked if the cytoplasmic retention of endogenous Rpb1 observed above in cells expressing exclusively Gpn3 Q279* was relevant for RNAPII transcriptional activity. For this purpose, we assessed global transcription in MCF-12A cells expressing wt or Q279* mutant Gpn3 (see Materials and methods section). We found that in cells expressing only Gpn3R Q279* the overall transcriptional activity was markedly decreased compared with cells expressing both the endogenous Gpn3 and the mutant Q279* (Fig. 2A) . The expression of the shRNA g193 did not affect overall transcription in cells expressing Gpn3R wt ( Fig. 2A) , confirming that Gpn3R wt is indeed functional. These results demonstrated that the cytoplasmic retention of Rpb1 in cells expressing only Gpn3R Q279* had a serious effect on global RNA synthesis, given at short times mainly by the transcriptional activity of RNAPII. Quantitation of our results in a large population of cells confirmed this conclusion (Fig. 2B) . Thus, the cytoplasmic retention of Rpb1 observed in cells expressing only the Gpn3 Q279* mutant described above is functionally relevant in terms of RNAPII transcriptional activity. It should be noted that although the molecular replacement of endogenous Gpn3 by Gpn3 Q279* is a very useful system to assess the functionality of the Gpn3 Q279* mutant in a cellular context, this condition does not represent the situation in skin cancer cells, where this mutation is heterozygous.
The Gpn3 Q279* nonsense cancer mutant enters the cell nucleus and inhibits nuclear export of Gpn1-EYFP
We next investigated the effect of the Q279* mutation on Gpn3 subcellular distribution in transiently transfected HEK293T cells. Wild-type Gpn3 localized exclusively to the cytoplasm but the Gpn3 Q279* mutant was detected in both, the cytoplasm and the cell nucleus (Fig. 3A) . As Gpn3 forms a tight protein complex with Gpn1 [9] , we evaluated if the nuclear entry of Gpn3 Q279* was associated with a change in Gpn1-EYFP distribution. Gpn1-EYFP expressed alone or together with Gpn3R wt localized exclusively to the cytoplasm in transiently transfected HEK293T cells (Fig. 3B) . However, when coexpressed with Gpn3R Q279*, Gpn1-EYFP distributed equally between the cytoplasm and the cell nucleus (Fig. 3B) , and this distribution was observed in most cells (Fig. 3C) . The Gpn1-EYFP nucleus/cytoplasm fluorescence ratio was clearly higher in cells coexpressing Gpn3R Q279* than Gpn3R wt (Fig. 3D) . Thus, the Gpn3R Q279* cancer mutant was able to disrupt Gpn1-EYFP nuclear export, probably in the form of the Gpn1-EYFP/Gpn3 protein complex [9] . These results are especially Fig. 1 . The Gpn3 Q279* nonsense colon and skin cancer mutant is defective to support RNA polymerase II (RNAPII) nuclear targeting. (A) Molecular replacement of endogenous Gpn3 by Gpn3R (RNAi-resistant) wt or Gpn3R Q279* nonsense mutant. Human mammary epithelial MCF-12A cells stably expressing either Gpn3R wt or the Q279* mutant were infected with retroviral particles expressing either the shRNA control g239 or the shRNA g193 to suppress endogenous Gpn3 expression. Total Gpn3 protein levels were assessed by Western blot with a Gpn3-specific rabbit antibody. As the Gpn3 Q279* mutant lacks only the last C-terminal six amino acids, the molecular weight is not distinguishable from wt Gpn3. Tubulin levels were assessed as control for protein loaded. (B) Subcellular distribution of Rpb1, the largest subunit of RNAPII, in MCF-12A cells expressing either Gpn3R wt or the Gpn3R Q239* cancer mutant. Cells expressing Gpn3R wt or Q279* mutant were infected with retroviral particles expressing either the shRNA control g239 or the shRNA g193 to suppress endogenous Gpn3. After selection with puromycin, cells were fixed with 3.7% formaldehyde in PBS and the subcellular distribution of Rpb1 was determined with a mouse monoclonal antibody. (C) Quantification of nucleus/cytoplasmic Rpb1 fluorescence in cells expressing only Gpn3R-wt or the Gpn3R Q279* nonsense mutant. The nucleus/cytoplasm fluorescence ratio was calculated using the software IMAGE J. Results are means AE SEM of at least 300 cells.
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interesting because they show that Gpn3 Q279* displays a gain of function in cells expressing Gpn3 wt, a property that increases the possibility that this mutant could affect the physiology of the cell even when present in a heterozygous state, as it is the case for skin cancer cells.
Disruption of the C-terminal PDZ-binding motif newly generated by the Q279* mutation in Gpn3 abolished Gpn3 Q279* ability to retain Gpn1-EYFP in the cell nucleus Next, we investigated the molecular mechanism behind the functional changes described above for the colon and skin Gpn3 Q279* cancer mutant. Analysis of the Gpn3 Q279* amino acid sequence in ELM [12] revealed in the Gpn3 Q279* mutant protein a consensus sequence for a PDZ-binding motif class 3 that is not present in the wild-type Gpn3 protein. In Gpn3 Q279*, the new C-terminal amino acid sequence MFDEYF* conforms nicely to the XXX(D/E)X (ACVILF)* consensus sequence commonly reported for this motif (Fig. 4A ) [12] . Most PDZ-binding motifs are located at the C-terminal end of a protein, and they invariably possess a hydrophobic amino acid at the very C-terminal position. In the PDZ-binding motif class 3, the amino acid at the À3 position strongly determines the specificity of the PDZ interacting domains [12] . To evaluate a possible involvement of this predicted PDZ-binding motif in the functional alterations we described above for Gpn3 Q279*, we studied the consequences of disrupting this motif by three different forms (Fig. 4A) . First, we added one amino acid to the Gpn3 Q279* C-terminal end to generate Gpn3 E280*, a mutant that will no longer possess the PDZ domain-binding motif, as the most Cterminal position will be Q279, a nonhydrophobic amino acid; second, we eliminated one amino acid from Gpn3 Q279* to generate Gpn3 F278*, where the last position will be occupied by a tyrosine, also a nonpermitted residue at this position in the PDZ-binding motif. And third, we mutated the glutamic acid at the À3 position of the predicted PDZ-binding motif in Gpn3 Q279* to alanine, and introduced the E276A mutation into Gpn3 Q279* to generate the Gpn3 E276A/Q279* double mutant. Thus, none of these three Gpn3 mutants will contain a functional PDZbinding motif class 3 any longer (Fig. 4A ). All these Gpn3 mutants were first tested in the Gpn1-EYFP delocalization assay described above. As shown in Gpn3 wt, was mainly cytoplasmic whereas in cells coexpressing the Gpn3R Q279* mutant, Gpn1-EYFP was in both the cell nucleus and cytoplasm, as expected. However, in cells cotransfected with Gpn1-EYFP and Gpn3R F278*, Gpn3R E280* or Gpn3 E276A/Q279*, Gpn1-EYFP was mainly cytoplasmic (Fig. 4B) . Importantly, the protein levels of all Gpn3 mutants were comparable (Fig. 4C) , indicating that none of the introduced mutations change Gpn3 stability. Analysis of a large population of transfected cells confirmed these findings (Fig. 4D) . These results strongly support our proposal that the functional alterations we observed in the Gpn3 Q279* cancer mutant result from the acquisition of a novel PDZbinding motif at the new C-terminal end of Gpn3 generated by the Q279* nonsense mutation.
Disruption of the PDZ-binding motif in Gpn3 Q279* cancer mutant rescues its deficit to support RNAPII-mediated transcription Next, we asked if the putative PDZ-binding motif generated by the Q279* mutation was also causally related to Gpn3 Q279* inability to support full RNAPII transcriptional activity. To this end, we generated the molecular constructs, retroviral particles and corresponding MCF-12A cell lines expressing Gpn3R wt, Gpn3R F278*, Gpn3R Q279*, or Gpn3R E280*. Global transcriptional activity at the single cell level in cells expressing only Gpn3 F278* or Gpn3 E280*, whose Ctermini do not conform to a PDZ-binding motif, was clearly higher than in cells expressing only Gpn3 Q279*, and much closer to the observed in control cells expressing Gpn3R wt (Fig. 5) . These results are again consistent with our conclusion that the functional decrease we described here for the Gpn3 Q279* cancer mutant is probably due to the acquisition of a novel PDZ-binding motif formed after the elimination of the last six amino acids on the C-terminal end of Gpn3 by the Q279* nonsense mutation. Consistent with this proposal is the fact that eliminating one amino acid from the Gpn3 Q279* mutant to generate the Gpn3 F278* alleviated most of the functional deficit in Gpn3 instead of worsen it, as it would be expected from a nonspecific perturbation of the C-terminal end of Gpn3 originated from a larger truncation.
Discussion
From the results obtained in this study, we concluded that the elimination of the last six amino acids from the Gpn3 C-terminal end caused by the Q279* nonsense mutation reported in colon [10] and skin [11] cancer patients, markedly changed the functional properties of Gpn3 at the cellular level. First, Gpn3 Q279* was highly inefficient to support nuclear targeting of Rpb1, the largest subunit of RNAPII. Second, the marked decrease in global RNA synthesis observed in cells expressing only Gpn3 Q279* indicates that this Rpb1 delocalization is indeed relevant for RNAPII transcriptional activity. Third, a fraction of Gpn3 Q279* accumulated in the cell nucleus. Fourth, Gpn3 Q279* inhibited Gpn1-EYFP nuclear export in transiently transfected HEK293T cells. Importantly, interference with Gpn1 nucleocytoplasmic shuttling may be at the root of Gpn3 Q279* inability to support RNA-PII nuclear targeting, as Gpn1 undergoes a nucleocytoplasm transport cycle [14] [15] [16] , mediated by a nuclear export sequence present at the Gpn1 C-terminal end [14] . This sequence has been proposed to be critical for Gpn1 function [6, 17] . Importantly, this transport cycle seems to occur even with Gpn1 is a complex with wild-type Gpn3 [9] . Nuclear retention of Gpn1 would be expected to be associated with the nuclear retention of the Ser5 CTD phosphatase RPAP2, as nuclear export of this protein depends on Fig. 4 . Disruption of the mutation-generated class 3 PDZ-binding motif in Gpn3 Q279* abrogates the recruitment of Gpn1-EYFP from the cytoplasm to the cell nucleus. (A) Analysis of Gpn3 Q279* primary sequence in ELM (The Eukaryotic Linear Motif resource) revealed that the new Gpn3 C-terminal end conforms to a PDZ-binding motif class 3 consensus sequence that is not present in the Gpn3 wild-type protein. Sequence alignment of the Gpn3 C-termini for Gpn3 wt and Gpn3 Q279*, as well as two Gpn3 variants with one amino acid more or one amino acid less respect to Gpn3 Q279* analyzed below, with the PDZ-binding motif class 3 consensus sequence. (B) Destroying the putative PDZ-binding motif in Gpn3 Q279* by removing or adding a single amino acid to its C-terminal end prevents the recruitment of Gpn1-EYFP from the cytoplasm to the cell nucleus. HEK293T/17 cells were cotransfected with plasmids encoding Gpn1-EYFP and Gpn3 F278*, Gpn3 Q279*, Gpn3 E280* or Gpn3 E276A/Q279* with calcium phosphate, as described in Materials and methods. Next day, cells were fixed and the nuclei were counterstained with DAPI. The subcellular distribution of Gpn1-EYFP was assessed under a fluorescence microscope. (C) Gpn1-EYFP and Gpn3 wt and mutants protein levels in B were assessed by Western Blot with specific antibodies as described in Materials and methods. Tubulin levels were employed as loading control. (D) The integrity of the PDZ domainbinding motif in Gpn3 Q279* is essential for the nuclear recruitment of Gpn1-EYFP. Gpn1-EYFP subcellular distribution was evaluated as 'cytoplasmic only' or 'cytoplasmic and nuclear' in a large population of transfected HEK293T/17 cells. Results are expressed as percentage of total transfected cells.
Gpn1. Gain of function is an important feature of truncated forms of the p53 family of proteins to generate their oncogenic properties [18, 19] . This gain of function observed in Gpn3 Q279* raises the possibility that this mutant may have a physiologically relevant effect in cancer cells even when present in a heterozygous state, which is the case for this mutation in skin cells [11] . A property that makes more likely that Gpn3 Q279* could play a critical role even at the heterozygous state is the fact that Gpn3 forms an obligated heterodimer with Gpn1 in human cells [9] . Fifth, the Q279* nonsense mutation generates a PDZ-binding motif at the new C-terminal end of Gpn3. And sixth, although in Saccharomyces cerevisiae Gpn3 Endogenous Gpn3 was replaced by RNAi-resistant versions of Gpn3: Gpn3R wt, Gpn3 F278*, Gpn3 Q279* or Gpn3 E280*. MCF-12A cells stably expressing the indicated versions of Gpn3 in the absence of endogenous Gpn3 were generated employing two retroviral vectors, the first to overexpress the indicated Gpn3 proteins, and the second to express the shRNA g193 to suppress the expression of endogenous Gpn3. (C) Quantitation of the global transcription activity experiments described in A was carried out employing the software IMAGE J.
Results are means AE SEM of at least 300 cells.
function is inhibited by the addition of a long C-terminal tag [6] , the altered properties of Gpn3 Q279* do not seem to arise from the loss of Gpn3 C-terminal integrity, but rather from the acquisition of this novel PDZ-binding motif not present in the wild-type Gpn3 protein. Importantly, the functional changes observed in Gpn3 Q279* mostly disappeared after disrupting the newly formed PDZ-binding motif, even by eliminating one more amino acid from Gpn3 Q279*, supporting our proposal that it is the acquisition of this motif, and not the loss of the C-terminal integrity what causes the observed functional changes in Gpn3 Q279*. Given that chromosome instability is a defining feature of cancer cells, it is worth noting that, at least in the yeast S. cerevisiae, Gpn3 plays an important role in chromosome segregation [6, 20] . If this function is conserved in human cells, as is Gpn3 involvement in RNAPII nuclear targeting [4, 6] , then it would be expected that, regardless of the moment when one copy of GPN3 disappears and the Gpn3 Q279* mutant is generated during the development of the tumor, the appearance of this Gpn3 mutant might be a physiologically relevant event, as the reduction in gene dosage and the functional alterations caused by the Q279* mutation may decrease Gpn3 function, which in turn would speed the chromosome instability characteristic of cancer cells. Interestingly, Minaker et al., [6] proposed that the faulty chromosome segregation observed in yeast expressing only Gpn3 mutants with a partial loss of function may be due to a partial RNAPII malfunction, as some of the same phenotypes have been observed in cells expressing functionally defective RNAPII subunits [21, 22] . It will certainly be of interest to determine in the near future if the functional changes we have demonstrated in this study for the Gpn3 Q279* mutant in a cellular context, have any contribution to the properties of colon and skin cancer cells.
